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Abstract
Over recent years, nuclear magnetic resonance (NMR) spectroscopy has developed into a 
powerful mechanistic tool for the investigation of G protein-coupled receptors (GPCRs). 
NMR provides insights which underpin the dynamic nature of these important receptors and 
reveals experimental evidence for a complex conformational energy landscape that is 
explored during receptor activation resulting in signalling. NMR studies have highlighted 
both the dynamic properties of different receptor states as well as the exchange pathways 
and intermediates formed during activation, extending the static view of GPCRs obtained 
from other techniques. NMR studies can be undertaken in realistic membrane-like 
phospholipid environments and an ever-increasing choice of labelling strategies provides 
comprehensive, receptor-wide information. Combined with other structural methods, NMR 
is contributing to our understanding of allosteric signal propagation and the interaction of 
GPCRs with intracellular binding partners (IBP), crucial to explaining cellular signalling.  
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Introduction
The first crystal structures of the GPCRs rhodopsin and the 2 adrenergic receptor 2AR) 
were released in 2000 and 2007 respectively [1,2]. Since then a surge of new crystal and 
more recently cryo-electron microscopy (cryo-EM) structures [3–5] of these proteins, which 
are central to cellular signalling pathways and are targeted by around 35% of drugs currently 
approved by the US Food and Drugs Administration (FDA) [6,7], has occurred. As 
understanding of GPCR structural biology has increased, the range of available crystal 
structures, spectroscopic and MD simulation studies have all pointed to the central role of 
GPCR dynamics and allosteric modulation in signalling [8]. NMR spectroscopists have 
combined established methodologies with new techniques to study the conformational 
energy landscape of these complex signalling proteins. These investigations have revealed 
the highly dynamic nature of GPCRs and the existence of functionally relevant low 
populated receptor states [9]. Together these studies are providing new insights into the 
role of conformational sampling for function and on the pathways of receptor activation, as 
well as contributing to the understanding of partial and biased agonism and allosteric 
modulation. Receptor specific differences in energy landscapes and dynamics are starting to 
become apparent. In parallel, many studies of GPCR interactions with ligands, essential to 
drug discovery, have been carried out for which NMR is a central technique [7,9]; however, 
in this current contribution we focus on recent protein-based studies. The combined 
information available from different structural techniques is providing a comprehensive 
molecular picture of these receptors and their signalling mechanisms, furthering our 
understanding of cellular processes and helping to guide the design of novel drugs that 
show improved properties.
Labelling
Traditional NMR isotope labelling approaches typically involve uniform 15N and 13C labelling 
with deuteration for large proteins and this is often suitable for GPCR interaction partners 
and their mimetics. In contrast, spectroscopic challenges related to fast spin relaxation 
together with difficulties in obtaining 13C, 15N uniformly labelled and perdeuterated 
receptors have so far hindered the success of comprehensive sequential assignment 
strategies for GPCRs. Instead, selective labelling approaches have been used with great 
success to investigate a subset of amino acid positions, with spectral assignments obtained 
via point mutations. For example, backbone amide positions in the 1-adrenergic receptor 
1AR) were 15N labelled at valines using insect cell expression [10]. For receptors that can 
be expressed in Pichia pastoris (P. pastoris), a uniform labelling strategy on a deuterated 
background is possible. For the A2A adenosine receptor (A2AAR), Gly backbone and Trp indole 
signals have been studied using uniformly 15N labelled samples on a deuterated background 
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[11,12]. However, P. pastoris is not a widely used expression host for GPCRs and most 
current studies rely on insect cell expression. Escherichia coli (E.coli) expression of a 15N 
labelled thermo-stabilized variant of rat neurotensin receptor 1 (NTR1) has also been shown 
[13]. 
The favourable spectroscopic properties of methyl groups have encouraged several studies 
to use side chain 13C methyl labelling of a range of amino acids, including methionine in the 
case of 1AR [14], 2-adrenergic receptor 2AR) [15,16],  receptor  [17], 
neurotensin receptor 1 (NTS1) [18], alanine for 2AR [19], isoleucine for A2AAR [20] and 13C-
dimethylated lysine via reductive methylation for  [21] and 2AR [22]. To decrease 
spectral overlap the number of labelled amino acids can be reduced via mutagenesis. While 
selective labelling results in reduced coverage of the protein compared to uniform labelling, 
further NMR active reporters may be introduced at key locations through mutagenesis, 
provided these do not interfere with receptor function. 
Deuteration is a key technique to improve NMR studies of GPCRs, by reducing the major 
contributions to relaxation [23]. In order to lower the proton density in the vicinity of 
reporter groups, carefully selected deuterated amino acid types along with algal amino acid 
mixtures may be used in insect cell expression [17,24]. The use of deuterated yeast extract 
has been shown for 2H,15N labelling of chemokine receptor type 5 (CCR5) and 1AR [25,26]. 
Further gains through optimisation of such methods can be expected in the future. D2O-
based expression is readily available in E. coli as shown for the leukotriene B4 receptor 
(BLT2) [27] and P. pastoris as shown for A2AAR [11,12,20]. 
It is also possible to use cell-free expression for GPCRs, however, so far this has not been 
widely used for NMR isotope labelling due to the challenges of producing folded, functional 
protein at good yields [28,29].
19F NMR studies rely on site-specific tagging of a reactive cysteine side chain thiol with a 
fluorine-containing reporter group [30,31]. A variety of tagging reagents are available that 
introduce groups that differ in their chemical and spectroscopic properties. Here the 
benefits of larger spectral dispersion need to be offset against the increased steric demands 
of bulkier tags. Larger tags may interfere with receptor function. Amongst the most 
successful reporter tags used on GPCRs are 2,2,2-trifluoroethanethiol (TET) [32–34], 3-
bromo-1,1,1-trifluoroacetone (BTFA) [35–37] and 2-bromo-4-trifluoromethylacetanilide 
(BTFMA) [38,39] (Figure 1). It may be necessary to reduce the number of cysteines via 
mutagenesis in order to avoid tagging at multiple sites or alternatively the chemical tagging 
reaction can be conducted with the GPCR still embedded in the membrane, which results in 
very high selectivity towards solvent-exposed cysteines [40]. 
In many NMR studies of unstable receptors, thermostabilised versions of GPCRs have been 
used as for X-ray crystallography. Thermostabilised receptors are often essential to obtain 
sufficient yields of stable protein for NMR studies and to enable investigations at elevated 
5
temperatures. Thermostabilisation shifts the receptor towards a particular state influenced 
by the properties of the orthosteric ligand in the presence of which stabilisation was 
conducted, frequently an inactive state. Furthermore, it increases the activation energy 
reducing the overall dynamics, observed in crystal structures and MD simulations, and 
demonstrated by NMR for the M90A mutant of 1AR [14,41]. Crystal structures of 
thermostabilised 1AR show near identical conformations regardless of agonist efficacy [42] 
while mutation of the conserved tyrosines Y2275.58 and Y3437.53 in 1AR  (superscripts refer 
to Ballesteros–Weinstein numbering scheme [43]) was shown to prevent G protein 
activation [10]. However, the amount of thermostabilisation may be reduced for NMR 
studies and dynamic regions, such as loops reintroduced allowing NMR to provide 
information on closer to wild type constructs.
Ligand binding in an efficacy dependent equilibrium
GPCRs are understood to function via conformational changes. The extended ternary 
complex model explains receptor function via a series of equilibria between an inactive 
state and an active, signalling form of the receptor bound to ligand and IBP, via an activated 
state that is competent to couple to G proteins and other IBPs [44,45]. 
In support of this multi-equilibrium model, NMR studies of ligand-bound receptors have 
confirmed the existence of multiple conformations. Recent work demonstrated that binding 
of orthosteric ligands of increasing efficacy to the 1AR and 2AR resulted in changes in the 
chemical shifts of key reporter residues (Figure 2A) in 2D correlation spectra, in a response 
that correlated with ligand efficacy [10,14,15]. This response was observed for 1AR 
methionine reporters M2235.54 and M2966.41 on transmembrane helix 5 (TM5) and TM6 
respectively using side chain methionine methyl group signals, and for V2265.57 on TM5, 
using the backbone amide signals of valine residues. Similar observations were made earlier 
for M822.53 in 2AR, located on TM2 adjacent to the ligand binding pocket [15] (Figure 2B-D). 
These results indicate the presence of fast exchange equilibria on the NMR timescale 
between the signals of the apo 1AR) or inverse agonist bound inactive form 2AR) of the 
receptor and the conformational state when bound to full-agonist. Measurements in 
reconstituted high density lipoprotein (rHDL), also known as lipid nanodiscs, and detergent 
micelles, suggested exchange on the millisecond (ms) timescale [24]. This implies that 
partial agonism relates to a conformational equilibrium in the transmembrane region of the 
receptor, with higher efficacy agonists increasing the population of a receptor form that is 
competent to bind G protein or other intracellular signalling partners that interact with the 
cytoplasmic side of the receptor.
Studies by 19F NMR using cysteine-attached CF3 probes revealed that next to the dynamic 
processes affecting the membrane core region, exchange was also present at the 
cytoplasmic side of the receptors, as evidenced by changes taking place at the tip of TM6 
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and TM7 in 2AR. A population shift between two exchanging conformational states, 
described as inactive and active, was seen in the presence of agonists of varying efficacy 
[34] (Figure 2E). In contrast to the faster conformational processes in the vicinity of the 
orthosteric binding pocket, indicative of relatively low free energy differences, this exchange 
was slow on the NMR timescale, likely due to the larger resulting chemical shift changes as 
well as slower kinetics, in agreement with the substantial cytoplasmic conformational 
rearrangements taking place. Overall this suggests a relatively loose, inefficient allosteric 
coupling of different regions of the receptor, which modulates the propagation of the signal 
towards the cytoplasmic side of the GPCR [34]. Similar observations relating to equilibria 
were also made for A2AAR 19F labelled at the tip of TM6, with partial agonist stabilising an 
active state at the expense of the inactive ensemble [39].
Low populated/intermediate states
While the above studies convincingly emphasize the dynamic nature of GPCRs they also 
indicate a more complex situation than suggested by the extended ternary complex model, 
with receptors adopting several additional conformational states that change their 
population in a ligand-dependent manner. These states are often invisible to other structure 
determination techniques either due to their low population, unfavourable exchange 
regime or inherent flexibility, or a bias in static structures driven by the requirement to form 
molecular contacts, thus trapping structures in a local energy minimum. Thus, the available 
static structures should be viewed as snapshots on a pathway between inactive (inverse 
agonist bound) and fully active state (bound to full agonist and G protein or an IBP mimetic). 
The additional low populated states are likely to play a crucial part in the versatility of GPCR 
signalling, allowing related receptors to achieve diverse functions. 13C NMR studies have 
highlighted that the ‘inactive’ state of GPCRs in fact involves several states, for example via 
the two signals observed for M82 in 2AR in the inverse agonist bound state [15] (Figure 2B). 
Two inactive conformations exchanging on the ms timescale are seen for the cytoplasmic 
part of TM6 in A2AAR using 19F NMR [39]. These are argued to represent states with the ionic 
lock salt bridge between TM3 (R1313.50) and TM6 (E2686.30) broken and formed respectively, 
consistent with crystal structures with (PDB accession code: 3PWH, [46]) and without an 
intact salt bridge (PDB accession code: 3EML, [47]; 3QAK [48]). Saturation transfer 
experiments indicate that the state with the open ionic lock is in equilibrium with an active 
state in both apo and partial agonist bound forms, with partial agonist causing a shift 
towards the active state. A more recent 19F NMR study on the A2AAR [49] using TET labelled 
A289C7.54 on TM7 shows two states in the apo and antagonist bound forms shifting to three 
states with full agonists. Based on the changes in the positions of proximal aromatic 
residues in antagonist and full-agonist bound static structures relative to the 19F reporter, 
the authors succeeded in assigning antagonist and full-agonist bound NMR states by 
comparing differences between expected and observed ring current shifts. The remaining 
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unassigned signals in the antagonist and agonist-bound states represent minor 
conformational states, shown to be mainly in slow exchange with the major states observed 
by crystallography [49]. In contrast, these minor states are not detected by crystallography. 
Studies on 2AR with a BTFA tag observed only an equilibrium between inactive states, 
suggesting a very low population of the corresponding active state [37], while studies using 
the TET tag observed an inactive-active equilibrium in the apo form [34]. Although there are 
discrepancies between the two studies, likely related to the constructs, 19F reporters and 
membrane mimetics employed, the unifying conclusion is the presence of multiple states 
that are in exchange, with different ligands shifting the equilibria between these states.
Pre-active states
Many studies on GPCRs conducted with a range of techniques agree with the observation 
that the full-agonist bound receptor state in the absence of an IBP does not reveal the fully 
active state [42,45,50]. Instead NMR studies highlight the existence of a pre-active or 
activation-intermediate state, which is in exchange with the inactive state. The extensive 
dynamics of this state indicate increased flexibility on the  timescale. Accordingly, for 
1AR bound to the full-agonist isoprenaline, the signal from M90 situated below the ligand 
binding pocket was lost and signals from M2235.54 and M2966.41, located in the extracellular 
halves of TM5 and TM6 respectively, showed temperature-dependent peak broadening [14] 
(Figure 2C). Results for the 2AR also suggest transitions between several states taking place 
on an intermediate timescale in the agonist-bound form, with weaker signals observed at 
the corresponding positions M2155.54 and M2796.41 and with MD simulations showing 
substantial mobility at the cytoplasmic ends of TM5 and TM6 [16].  Temperature 
dependence for 19F signals on TM6 and TM7 (Cys2656.27 and Cys3277.54) in TET-tagged 2AR 
indicates slow exchange between active and inactive states with the active state showing 
greater flexibility amongst a range of conformations [34]. Temperature dependence of 
methionine 13C methyl-labelled  was also observed for M2455.49 indicating fast-
exchange between multiple conformations in the full-agonist bound form, with biased full-
agonists shifting the equilibrium towards the G protein, or  activating forms [17]. 
Based on 19F NMR data, the exchange between the inactive and active states involving TM6 
and TM7 of 2AR revealed an enthalpy value of  ~40 kJmol-1, indicating extensive 
molecular rearrangements, with an exchange rate constant of < 10 s-1 (280 K) [32]. The 
exchange was shown to be enthalpically disfavoured and entropically favoured [32,36].  
Faster side chain dynamics on the ps-ns timescale were observed for A2AAR in the agonist-
bound state in comparison to the inverse agonist bound form when using a triple quantum 
relaxation experiment in combination with isoleucine  13C labelled receptor [20]. A 
quantitative assessment of S2 order parameters for 2AR was obtained for different ligand-
bound states, indicating the greatest flexibility for the pre-active state. [36].
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Overall the various NMR studies corroborate a situation where the full-agonist bound form 
represents an on-pathway intermediate to the ternary, fully active, G protein bound state 
seen in crystal structures. This pre-active/activation-intermediate state remains in exchange 
with one or more inactive states with agonists of increasing efficacy shifting the population 
towards the more flexible pre-active state, while inverse agonists bias towards the inactive 
state(s).The pre-active state is conformationally dynamic, showing both increased fast 
timescale motions (ps-ns dynamics) and sampling a range of conformations on a  
timescale, that enable a receptor to couple to different intracellular binding partners e.g. G 
proteins or  (Figure 3). 
Fully active/ternary complexes
GPCRs are known to bind to a range of intracellular signalling proteins such as G proteins 
and arrestins, which enables signalling via multiple downstream pathways. Different 
receptors show selectivity for, and different ligands bias receptors towards the different 
pathways. NMR studies have typically used nanobodies e.g. Nb80 [10,16,51], Nb6B9 [14,52] 
and Nb33 [21] or the G  C-terminal peptide [39] as mimics for G  proteins to stabilize the 
fully active state of a receptor. While overall structures of receptors in ternary complexes 
with nanobodies or G protein are very similar, small conformational differences between 
the ternary complexes have been described e.g. in the case of 2AR and OR [51,53–56]. 
Substantial chemical shift changes in 1AR are observed on binding of a G protein mimic in 
helices TM3-TM6, consistent with large scale conformational changes in the receptor and 
indicating the G protein bound form is a state distinct from that of the pre-active/activation-
intermediate [10,14,16]. Changes in 1AR extend from the ligand-binding pocket to the 
extracellular and cytoplasmic side of the receptor indicative of long-distance communication 
across the membrane [10,14]. Similarly in the case of the lysine 13C-dimethylated  
binding of Nb33 and full-agonist is needed to stabilise the fully active state with substantial 
changes observed in TM5 and TM6 and a two-way connection between the extracellular 
ligand-binding and intracellular G protein coupling domains detected [21]. In this study large 
changes in ICL1 and H8 are observed in the presence of full-agonist but without Nb33, 
suggesting that this region may be the site of initial interaction between G protein and GPCR 
[21].
19F NMR studies of 2AR bound to Nb80 and full-agonist confirm that TM6 adopts a new 
conformation, which is conformationally less mobile as shown by CPMG measurements 
[37]. The latter is consistent with the methyl-group signal intensity analysis of 1AR 
indicating rigidification on the  timescale of the receptor in the IBP bound form [14] 
(Figure 2G). This data suggests further that although motionally more restricted, the ternary 
complexes retain an inherent amount of mobility rather than becoming completely rigid.
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For 1AR in the ternary complex with Nb6B9, residues in TM4-6 and ICL2 revealed an 
equilibrium between two conformations in fast-exchange, with the equilibrium position 
correlating with ligand-efficacy (Figure 2F). Thus, the two conformations were postulated as 
a less active coupled ternary form, likely representative of basal receptor activity, and a 
fully-active ternary form with full-agonist and a G protein mimic nanobody bound [14] 
(Figure 3). Accordingly, higher efficacy agonists not only increase the propensity to bind IBP 
via increasing the population of a pre-active state of the receptor, but also affect the 
conformation of the resulting active ternary signalling complex, likely influencing the 
coupling efficiency to G protein and hence the level of signalling potentially through 
formation of a tighter or looser coupled complex [14,57]. Thus, ligand efficacy is reflected 
both in the inactive/pre-active state equilibrium of the receptor as well as in the equilibrium 
involving less/more active ternary complexes, which can be hypothesised translates into a 
ligand influencing both the initial interaction with an IBP (propensity to bind, and IBP 
selectivity) as well as the subsequent signalling activity through modulation of the GPCR-IBP 
interaction (Figure 3).  
The allosteric coupling interplay of different receptor regions remains a prominent feature 
of GPCR-IBP interactions revealed by NMR and links into the important question of biased 
signalling. A key NMR study investigated phosphorylation of the 2AR C-terminal region by 
GPCR kinases (GRKs), via a segmental labelling approach, indicating that the phosphorylated 
C-terminus adheres to the membrane potentially forming part of the  binding 
interface. Conformational changes at M2155.54 and exchange-broadening of M2796.41 in the 
full-agonist bound, phosphorylated state were indicative of the receptor sampling multiple 
conformations, suggesting that tail-phosphorylation causes the 2AR to adopt a  
binding conformation, leading to selectivity for the  signalling pathway and may 
represent an on-pathway activation intermediate [58].
Lipid environment
Most structural studies of GPCRs so far have been carried out using detergent micelles, with 
n  (DDM) and lauryl-maltose neopentyl glycol (LMNG) frequently used 
for NMR studies, in some cases doped with cholesterol hemisuccinate (CHS). Differences in 
receptor behaviour that relate to changes in the environment are clearly observed, with for 
example three distinct states in 19F NMR observed for 2AR in LMNG, compared to only two 
in DDM, an effect attributed to the different off-rates of the two detergents [35]. NMR 
studies have enabled comparisons of GPCR structures and dynamics in different media with 
membrane scaffold protein (MSP) nanodiscs (rHDL nanoparticles) a popular choice to enable 
studies of membrane proteins in a lipid-like, close-to-native environment [24,59]. A detailed 
comparison of the 2AR in DDM vs POPC:POPG nanodiscs indicated slower exchange rates 
between the different conformations of M82 in the lipid environment, along with a shift in 
the equilibrium position towards the active conformation in response to different lipids [24]. 
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Due to the large size of the nanodisc particles and hence the slower rotational diffusion, 
such investigations strongly benefit from receptor deuteration. Saposin-derived 
phospholipid nanoparticles have also been proposed as a suitable medium to study GPCRs, 
providing a membrane-like environment with the benefits of a high protein incorporation 
efficiency [60]. Although the number of studies in any of the lipid-based mimetics is still 
small, the available evidence suggests that phospholipids exert a significant effect on the 
energetics and kinetics of GPCR activation and also affect receptor interaction with 
intracellular binding partners [61,62]. Studies involving binding partners that are unstable in 
detergents are aided through the use of lipid membrane mimetics, for example the binding 
of heterotrimeric G protein to thermostabilized NTR1 embedded in circularized nanodiscs 
[13].
Relating solution NMR to static structure information
In assessing the structural implications of NMR investigations, it can be helpful to relate the 
data to existing X-ray and cryo-EM structures. NMR studies based on selective labelling 
approaches primarily use chemical shift changes to detect variations in protein 
conformations, which may relate to states observed in crystal structures, or to other unseen 
or dynamic states, as discussed above. Changes in chemical shifts result from variations in 
the electronic environment. Thus, residues in the immediate proximity of an NMR reporter 
have the greatest influence. Of particular value are ring current shift contributions from 
aromatic amino acids. For short distances between an aromatic ring and the NMR probe 
these have been shown to correlate with observed 1H and 19F chemical shift changes for 
both methyl and CF3 groups [14,15,63]. The measured ring current shifts can be compared 
with the calculated expectations [64,65] based on static structures. Conversely, the absence 
of chemical shift changes at a reporter site may reflect a lack of aromatic residues in its 
vicinity. Such considerations are relevant for choosing the location of potential reporter 
sites, and for interpreting NMR data.
Outlook
Solution NMR has provided considerable insight into the mechanistic understanding of 
GPCRs through the characterization of conformational dynamics and their timescales, the 
description of conformational equilibria, by providing evidence of the existence of low 
populated states, and by delineating allosteric networks involved in the ligand-stimulated 
signal transfer. This trend looks set to continue as more receptors are investigated. Future 
studies are likely to focus even more on the dynamic nature of GPCRs and will provide a 
more quantitative description of the phenomena described above. This will help to explain 
some of the inherent similarities as well as disparities in the behaviour of different GPCRs, 
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including closely related receptor sub-types. Several studies have already extracted dynamic 
parameters and exchange kinetics using 19F CPMG experiments [37,38] or saturation 
transfer [49], as well as limited side chain dynamics [20]. However, to fully realise the 
potential of relaxation data for backbone and side chain residues, and thus provide a 
protein-wide description of receptor dynamics enabling correlation with MD simulations, 
protocols for deuteration of receptors will need to be further developed to provide 
adequate signal-to-noise. High levels of deuteration are currently only available in E. coli or 
P. pastoris. 
As discussed earlier, like X-ray crystallography, some NMR studies conducted on inherently 
unstable GPCRs rely on thermostabilised mutants to ensure sufficient receptor stability 
throughout NMR measurements. In order to accurately describe receptor dynamics, 
thermostabilisation will need to be reduced, which has been demonstrated, for example 
with the 1AR [10,14]. Further development of expression techniques and use of lipid-based 
membrane mimetics will likely allow thermostabilisation to be reduced further. Crucially, 
NMR studies are able to investigate flexible regions of receptors e.g. loops, which are likely 
to be essential for receptor function and we expect future studies will further investigate 
these regions including with wild-type sequences. 
The relevance of lipids is only beginning to be understood and the introduction of powerful 
membrane mimetics in the form of nanodiscs and nanoparticles, possibly in combination 
with receptor deuteration, will enable investigation of stoichiometric interactions between 
lipids and receptors and their role as allosteric modulators as well as bulk effects related to 
the lipid bilayer and its composition. In addition, solution NMR studies to date have only 
explored a small subset of class A GPCRs (Table 1), so studies on other receptors and 
receptor classes will reveal how far current observations are general principles.
Using alternative nuclei may also prove interesting. Examples include 31P to investigate 
detergent/lipid components, as well as metal ions such as 23Na NMR used in a recent study 
to investigate the binding dynamics of Na+ ions in the A2A receptor via CPMG experiments 
[38]. This highlighted a connection between metal ion dynamics and the activation process. 
Using such alternative reporters will provide new insights into the versatility of GPCR 
receptor activation in the future.
Conclusion
Solution NMR studies have explored several class A GPCRs (Table 1) using a variety of 
backbone and side chain reporters as well as reporter tags. This has enabled NMR to 
investigate the underlying receptor dynamics and exchange kinetics of class A receptors. 
Based on the limited number of studies available, investigations have revealed that 
receptors sample multiple states in equilibrium, with agonists of different efficacies altering 
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the populations of the different receptor states. The full agonist bound state is observed to 
show increased conformational exchange dynamics  timescale), potentially priming 
the receptor to interact with different intracellular binding proteins. Biased agonists are 
observed to influence the population of the various pre-active states thus activating 
different pathways to varying amounts. On interaction with an intracellular binding partner 
and full agonist, the receptor adopts a less dynamic, fully active state. Thus, GPCRs are seen 
to occupy a complex energy landscape, with some general principles shared across the 
receptors investigated to date, and also receptor specific differences noticed.  The resulting 
receptor conformational and exchange dynamics are likely to be critical in specifying the 
activation pathway and level of activation for a particular GPCR. Solution NMR has proved 
central to the general understanding of GPCRs and future studies will deepen our 
knowledge of this essential class of proteins, of the receptor specific differences, as well as 
exploring the variations among non-class A receptors.
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system Labelling NMR experiments Reference
A2AAR P. pastoris LMNG 19F-BTFMA 19F; 1D, STD [39]
A2AAR P. pastoris LMNG
19F-BTFMA; 
metal ions
19F, 23Na+, 25Mg+; 1D, 
CPMG [38]
A2AAR P. pastoris LMNG/CHS U-15N, ~70% 2H 1H,15N TROSY [12]
A2AAR P. pastoris LMNG/CHS U-15N, ~70% 2H 1H,15N TROSY [11]
A2AAR P. pastoris DDM 13CH3 Ile  / 2H 
1H,13C HMQC, 3Q-
relaxation [20]
1AR Sf9 or Sf21 LMNG 13CH3-Met 1H,13C-HMQC [14]
1AR High five DM 15N-Val 1H,15N HSQC [10]












C-tail: U-[ 2H, 
13C, 15N] or 




2AR Sf9 DDM 13CH3-Met 1H,13C HSQC [16]










2AR Sf9 LMNG 19F-BTFA 19F; 1D, T1, T2 [36]












HMQC; 1H,13C HSQC [22]







CCR5 Sf9 DDM u-2H,15N 1H,15N TROSY [26]
NTS1 E. coli DDM 13CH3-Met 1H,13C-HMQC [18]
NTR1 E. coli
DMPC/DMPC 









A2AAR, A2A adenosine receptor; 1AR, 1-adrenergic receptor; 2AR, 2-adrenergic receptor; 
BLT2, leukotriene B4 receptor; BTFA, 3-bromo-1,1,1-trifluoroacetone; BTFMA, 2-bromo-4-
trifluoromethylacetanilide; CCR5, C-C chemokine receptor type 5; CHS, cholesterol 
hemisuccinate; DDM, dodecyl maltoside; EXSY, exchange spectroscopy; HMQC, 
heteronuclear multiple-quantum correlation; HSQC, heteronuclear single-quantum 
correlation; LMNG, lauryl maltose neopentyl glycol;   receptor; NTS1, NTR1, 
neurotensin receptor 1; STD, saturation-transfer difference; TET, 2,2,2-trifluoroethanethiol; 
TROSY, transverse relaxation optimized spectroscopy; 3Q-, triple quantum.
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Figure captions
Figure 1 | Functional studies of GPCRs by NMR: NMR studies of GPCRs require 
incorporation of an NMR active isotope. Amino acid type selective or uniform 15N labeling 
[10–12], or 13C labelling of methyl groups has been used [14–20], in a range of expression 
hosts, with most studies using insect cell expression. NMR active groups can also be 
incorporated post-translationally via attachment of 19F-containing tags to reactive cysteine 
thiol groups [30–40], or via reductive 13C methylation of lysine groups [21,22]. High levels of 
receptor deuteration that improve the performance of NMR experiments can be obtained in 
E. coli [27] and P. Pastoris [11,12,20], with comparable methods being less established in 
insect cells [17,24,25].  NMR samples can be prepared with the GPCR solubilized in 
detergent micelles or embedded in a phospholipid-bilayer as part of an MSP nanodisc 
[24,59] or saposin nanoparticle [60]. Depending on the isotope labelling scheme a range of 
1D and 2D NMR spectra (1H,15N TROSY; 1H,13C HMQC) are typically recorded to monitor the 
conformational response of the receptor to a range of activating (agonists)/inactivating 
ligands (inverse agonists), lipids, IBPs etc. Residue specific assignments frequently require 
the introduction of point mutations. Conformational interchange and dynamics taking place 
on a range of timescales can be investigated for every residue available and quantitated via 
CPMG, STD, 3Q-relaxation, T1, T2 and EXSY experiments, for example. Integrated with data 
from other studies, the resulting NMR information can be used to propose a model that 
informs on the conformational plasticity of the receptor, providing insight into the dynamic 
nature of the GPCR in the context of ligand-based activation, allosteric activation, G protein 
signaling,  arrestin signalling, partial agonism, biased agonism etc. (Figure 3). The studies 
on different receptors can be compared, revealing receptor specific differences due to 
variations in their energy landscape. 
Figure 2 | Conformational equilibria observed by NMR related to adrenergic receptor 
activation: 
A) Locations of the investigated residues of 1AR and 2AR mapped onto the crystal 
structure of 1AR in the inactive state (PDB accession code: 2RH1). Residue positions use the 
GPCRdb numbering scheme [66]. B-G) Representative regions of NMR spectra from studies 
on 1- and 2AR emphasizing the dynamic nature of GPCRs and the conformational response 
of the receptors to ligands and IBPs. B) Overlay of a 1H,13C HMQC spectra region of 2AR 
showing the response of the M822x53 signal to binding of ligands of increasing efficacy: 
carazolol (black), alprenolol (cyan), tulobuterol (green), clenbuterol (purple), formoterol 
(red). With M822x53 located in the proximity of the orthosteric binding pocket, a gradual 
change from the inverse agonist carazolol bound receptor to the full-agonist formoterol 
bound state is observed, indicating a conformational equilibrium between inactive (M82U) 
and pre-active (M82A) receptor forms. A second inactive, less populated conformation 
(M82D) is observed in the carazolol bound state. C) The combined 1H,13C position of the 
signal of M2235x54 on TM5 of 1AR correlates with the efficacy of the agonist - apo receptor 
(blue), carvedilol (red), 7-methylcyanopindolol (orange), cyanopindolol (green), xamoterol 
(yellow), salbutamol (purple), isoprenaline (pink) - suggesting that this area of the receptor 
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is exchanging rapidly between two states, corresponding to inactive (I) and pre-active (A) 
receptor in equilibrium. The population of the two states is determined by the ligand 
efficacy. In the full-agonist, isoprenaline bound state (A) a decrease in signal intensity occurs 
and variable temperature experiments (308 K, 298 K, 288 K) reveal multiple resolved peaks 
for M223 at lower temperature. This implies additional slower s-ms timescale exchange 
processes for the pre-active state (A), revealing increased plasticity (A’,A’’,A’’’) of the full-
agonist bound receptor (see Fig. 3A). D) Overlay of 1H,15N TROSY spectra showing the 
response of 1AR V2265x57 backbone amide to agonists (apo (black), atenolol (ATE, cyan), 
carvedilol (CAR, red), alprenolol (ALP, purple), cyanopindolol (CYA, green), dobutamine 
(DOB, orange), isoprenaline (ISO, blue)). Correlation between the combined 1H,15N chemical 
shifts and the efficacy of the bound ligands is indicative of the propagation of the ligand 
stimulus from the orthosteric binding pocket towards the cytoplasm. E) 19F NMR signals of 
2AR C2656x27 and C3277x54 probe conformational changes on the cytoplasmic side of the 
receptor. Deconvolution of the experimental data (black) in the apo and e.g. isoetharine 
bound state show a slow exchanging equilibrium between inactive ((I), cyan) and active ((A), 
red) receptor conformations. The slow exchange is in agreement with the large 
conformational displacements affecting this region of the receptor. The population of the 
two conformations (I) and (A) is sensitive to the orthosteric ligand bound, with more (A) 
state being populated with higher efficacy of the agonist. F) Overlay of 1H,13C HMQC spectra 
of 1AR coupled to the G protein mimetic nanobody Nb6B9, showing the active state of the 
receptor in ligand-free form or bound to full-agonist isoprenaline, respectively. Residues 
M1784x62 on TM4/EL2 and M2966x41 on TM6 show distinct changes, indicating 
conformational differences for the two active receptor forms displayed. The insert shows an 
overlay zoomed in on M2966x41 with the Nb6B9 coupled receptor bound to a range of 
agonists: apo (blue), cyanopindolol (green), salbutamol (purple), isoprenaline (pink), 
adrenaline (brown). Signal positions correlate with the efficacy of the ligand similar to the 
ligand-only bound receptor (Fig. 2A), indicating that the ternary complex is rapidly 
exchanging between two conformations (AG- and AG+) (Figure 3). G) Dynamics of 1AR 
M2235x54 and M2966x41 (TM5 and TM6 respectively) expressed as normalized intensity 
variations relative to M153 (ICL2) Apo (blue), agonist bound (orange; 7mC, 7-methyl-
cyanopindolol; ADR, adrenaline; CVD, carvedilol; CYA, cyanopinodolol; ISO, isoprenaline; 
SLB, salbutamol) and ternary complex receptor states (red) are compared. Lower values 
indicate increased mobility on the s-ms timescale. Increased dynamics of the full-agonist 
bound receptors (ISO and ADR) are observed. Ternary complex full-agonist bound states are 
much less dynamic although maintain a residual level of mobility relative to the reference, 
M153.  Part B is adapted with permission from [15], Springer Nature Limited. Parts C, F, and 
G are adapted with permission from [14], licensed under Creative Commons 4.0. Part D is 
adapted with permission from [10], Springer Nature Limited. Part E is adapted with 
permission from [34], Science/AAAS.
Figure 3 | Conformational dynamics of GPCRs:  A) Representative GPCR signalling model for 
a class A receptor based on NMR data for the 1AR and 2AR (see Fig. 2 for selected NMR 
spectra) [10,14,15,34]. The majority of the depicted equilibria conformational states are in 
agreement with the extended ternary model of activation [44]. Receptor states are shown 
colour coded with the inactive (I) form in blue, the pre-active (A) receptor in orange and the 
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fully active (AG) receptor coupled to an IBP shown in purple, illustrating the large outward 
movement of the cytoplasmic half of TM6 in the active state which enables binding of IBPs. 
The equilibrium between the (I) and the (A) forms represents orthosteric ligand-dependent 
activation. Low-level population of the (A) form in the absence of orthosteric ligand (apo 
state) represents the basal activity level of the receptor. The ligand-bound inactive receptor 
is shown in two forms, (I1) and (I2), that are stabilized to different amounts by inverse 
agonists. (I1) is in a ligand-efficacy dependent equilibrium with the highly dynamic pre-active 
state (A), preferentially populated when bound to full-agonists.  The increased plasticity of 
this full-agonist bound state, as revealed by 13C NMR, is indicated by multiple conformations 
(A'), (A'') and (A''') that are interchanging on the s-ms timescale. The activation model 
suggests that different conformations of the pre-active state vary in their ability to engage 
with a range of IBPs, resulting in signaling via G protein,  arrestin and other IBPs. For 
simplicity only the cytoplasmic interaction of (A’) with G protein is shown. The agonist 
bound, fully active G protein coupled receptor is in equilibrium between (AG-) and (AG+) 
states with the populations determined by the efficacy of the agonist. It is suggested that 
(AG-) and (AG+) correspond to less and more active forms of the ternary complex. Thus, 
partial agonism manifests in both the (I)/(A) ligand-efficacy dependent equilibrium and in 
the equilibrium between a less and a more active ternary receptor form, with full-agonists 
increasing the population of the more active form.  B) Based on 13C methyl methionine NMR 
data on 1AR the less (AG-), and more active (AG+) coupled receptor forms show 
conformational differences on TM5 and TM6 (Fig. 2E) [14]. These differences are 
hypothesized to modulate the receptor’s ability to interact with G , which may regulate 
signalling via altering the GEF activity of the receptor, affecting the rate of GDP release. Thus 
partial agonists increase the population of (AG-) which may reduce the turnover of GTP and 
hence receptor signaling. In contrast, full-agonists maximize the population of (AG+) and 
hence may accelerate the release of GDP, leading to higher signaling efficacy via the G 
protein pathway.
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